Teacher Retirement System of Texas Sells 242,170 Shares of Pfizer Inc. $PFE

Teacher Retirement System of Texas lessened its holdings in Pfizer Inc. (NYSE:PFE) by 10.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,088,694 shares of the biopharmaceutical company’s stock after selling 242,170 shares during the quarter. Teacher Retirement System of Texas’ holdings in Pfizer were worth $50,630,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in PFE. GKV Capital Management Co. Inc. bought a new stake in Pfizer during the first quarter worth $27,000. Curio Wealth LLC raised its position in Pfizer by 36,600.0% during the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 1,098 shares in the last quarter. Bayforest Capital Ltd bought a new stake in Pfizer during the first quarter worth $28,000. North Capital Inc. bought a new stake in Pfizer during the first quarter worth $28,000. Finally, Harbor Asset Planning Inc. bought a new stake in Pfizer during the second quarter worth $29,000. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Bank of America upped their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. UBS Group reaffirmed a “neutral” rating and set a $28.00 price target on shares of Pfizer in a research report on Wednesday, October 1st. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a report on Saturday. Morgan Stanley decreased their price objective on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a report on Friday, October 10th. Finally, Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Pfizer has an average rating of “Hold” and a consensus price target of $28.13.

Pfizer Trading Up 0.5%

PFE stock opened at $24.79 on Monday. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $29.17. The company has a market capitalization of $140.92 billion, a PE ratio of 13.18, a price-to-earnings-growth ratio of 0.82 and a beta of 0.55. The company’s 50-day simple moving average is $24.87 and its 200 day simple moving average is $24.20. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period last year, the firm earned $0.60 earnings per share. Pfizer’s revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is currently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.